Bioactivity:

Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM). Rigosertib is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition of the PI3 kinase/Akt pathway, promotes the phosphorylation o

CAS nr:

592542-59-1

Purity:

98%

Molecular Weight:

451,49

SMILES:

COC1=C(C=C(C=C1)CS(=O)(=O)/C=C/C2=C(C=C(C=C2OC)OC)OC)NCC(=O)O

Formula:

C21H25NO8S

Pathway:

Angiogenesis,Tyrosine Kinase/Adaptors,Angiogenesis,Tyrosine Kinase/Adaptors,PI3K/Akt/mTOR signaling,Cell Cycle/Checkpoint,Tyrosine Kinase/Adaptors,Angiogenesis,Apoptosis,Cell Cycle/Checkpoint,Angiogenesis,Tyrosine Kinase/Adaptors,Cytoskeletal Signaling

Target:

PDGFR,PDGFR,FLT,FLT,PI3K,PLK,Src,Src,Apoptosis,CDK,Bcr-Abl,Bcr-Abl,Bcr-Abl